Clinical Trials Logo

Sickle Cell Crisis clinical trials

View clinical trials related to Sickle Cell Crisis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05373771 Recruiting - Sickle Cell Crisis Clinical Trials

Sickle Cell Improvement: Enhancing Care in the Emergency Department

SCIENCE
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

Sickle cell disease (SCD) is an inherited blood disorder affecting approximately 36,000 children in the United States, approximately 90% of whom are Black. The disease is characterized by recurrent, severe pain crises which result in high rates of emergency department visits and hospitalizations, and decreased quality of life. The National Heart, Lung and Blood Institute, as well as the American Society of Hematology, have endorsed pain management guidelines regarding the timeliness of care for children presenting with these acute pain crises. These evidence-based guidelines are infrequently followed, resulting in increased pain and hospitalizations. In additional to other barriers to following the guideline, structural racism has been proposed as a significant contributor and the New England Journal of Medicine recently called for the institution of SCD-specific pain management protocols to combat structural racism and reduce time to opioid administration. The investigators' long-term goal is to improve the care and health outcomes of children with acute painful vaso-occlusive crisis treated in the emergency department. The overall aim of the investigators is to test a care pathway using multifaceted implementation strategies to increase guideline adherent care for children in the emergency department with acute painful vaso-occlusive crisis.

NCT ID: NCT04076748 Recruiting - Sickle Cell Crisis Clinical Trials

Evaluation of the Efficacy of Intra-nasal Sufentanil for Analgesia of Vaso-occlusive Crisis in Sickle-cell Adults.

DREPSUFINDOL
Start date: July 20, 2021
Phase: Phase 3
Study type: Interventional

The analgesic treatment for vaso-occlusive crisis (VOC) in sickle-cell patients is an emergency. The reference treatment is morphine, which requires a venous way sometimes difficult to obtain in these patients. Sufentanil intranasal has been shown to be effective in traumatology. The objective is to evaluate, in VOC, the efficacy of intranasal sufentanil relayed by morphine IV compared to the usual protocol, Equimolar Mixture of Oxygen-Nitrous Oxide (EMONO) relayed by morphine intravenous (IV).

NCT ID: NCT03431285 Recruiting - Sickle Cell Crisis Clinical Trials

Ketamine for Acute Painful Crisis in Sickle Cell Disease Patients

Start date: January 1, 2018
Phase: N/A
Study type: Interventional

Investigators hypothesize that administration of ketamine for pain relief in sickle cell patients with vaso-occlusive crisis early on will lead to a more rapid improvement in pain score and less narcotic requirement.